Outside the Guidelines: Denosumab Overuse in Prostate Cancer Outside the Guidelines: Denosumab Overuse in Prostate Cancer

Many men with castration-sensitive prostate cancer receive the bone-modifying agent to prevent skeletal-related events, but that practice is not recommended and costs Medicare millions annually.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news